Blaine Robinson, Ph.D

Dr. Blaine Robinson joined LLS in 2011 and was recently promoted in January 2025 to Vice President of the Therapy Acceleration Program (TAP), the venture philanthropy initiative aiming to accelerate high-risk, innovative blood cancer therapeutics. He works closely with the entire LLS Research team and is responsible for identifying and evaluating potential blood cancer drug development opportunities for investment. He has over 20 years of research, drug development and project management experience in the blood cancer field. During his tenure at LLS, he has managed over 25 TAP partnerships and has helped perform scientific due diligence on hundreds of opportunities for TAP.

Prior to LLS, Dr. Robinson worked at the Children’s Hospital of Philadelphia where he completed a two year postdoctoral fellowship and continued on as a Research Associate for five years where he was in charge of all research laboratory operations and project management duties in a pediatric leukemia laboratory. He received his Ph.D. degree in Pharmacology at the University of Michigan in Ann Arbor, MI.